This Article Full Text Full Text (PDF) All Versions of this Article: 110/5/496    most recent 01.CIR.0000137122.95108.52v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gherli, T. Articles by Beghi, C. Search for Related Content PubMed PubMed Citation Articles by Gherli, T. Articles by Beghi, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID WARFARIN Related Collections Coagulation Aggregation Coumarins Platelet function inhibitors Thrombosis risk factors Valvular heart disease CV surgery: aortic and vascular disease CV surgery: valvular disease Acute Cerebral Hemorrhage Embolic stroke Anticoagulants Antiplatelets

(Circulation. 2004;110:496-500.)
© 2004 American Heart Association, Inc.

Original Articles

Comparing Warfarin With Aspirin After Biological Aortic Valve Replacement

A Prospective Study

Tiziano Gherli, MD; Andrea Colli, MD; Claudio Fragnito, MD; Francesco Nicolini, MD; Bruno Borrello, MD; Stefano Saccani, MD; Roberto D’Amico, StatSci; Cesare Beghi, MD

From the Department of Cardiac Surgery, University of Parma, Parma (T.G., A.C., C.F., F.N., B.B., S.S., C.B.), and Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena (R.D.), Italy.

Correspondence to Andrea Colli, MD, Department of Cardiac Surgery, University of Parma, Via Gramsci 13, 43100 Parma, Italy. E-mail colli.andrea{at}libero.it

Received January 22, 2004; revision received April 13, 2004; accepted April 14, 2004.

Background— Patients with prosthetic heart valves have a higher risk of developing valve thrombosis and arterial thromboembolism. Antithrombotic therapy in the early postoperative period after biological aortic valve replacement (BAVR) is controversial. The American College of Cardiology/American Heart Association and European Society of Cardiology guidelines recommend the use of warfarin for the first 3 months after BAVR, although the American College Chest Physician guidelines suggest that the recommendations are very weak and that the risk/benefit is unclear. This prospective study investigated the efficacy of postoperative warfarin compared with aspirin in patients after aortic valve replacement.

Methods and Results— Patients undergoing BAVR between 2001 and 2002 received 2 antithrombotic therapies: 141 patients received warfarin for the first 3 months, and 108 patients received only aspirin. The major end points evaluated were the rate of cerebral ischemic events, bleeding, and survival. There were 3 and 5 postoperative cerebral ischemic events between 24 hours and 3 months for patients treated with aspirin and warfarin, respectively. After 3 months, the incidence of cerebral ischemic events did not differ between the 2 groups. The rate of major bleeding events, the stroke-free survival, and the overall survival rates were not statistically significant between the warfarin and aspirin groups.

Conclusions— There seem to be no advantages in performing early anticoagulation therapy compared with a low-antiplatelet regimen with regard to early cerebral ischemic events, bleeding, and survival. Currently there is no evidence to support the fact that warfarin is more effective than aspirin.

Key Words: anticoagulants • aspirin • surgeryvalves • prosthesis

This article has been cited by other articles:

				J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]

				D. N. Salem, P. T. O'Gara, C. Madias, and S. G. Pauker Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 593S - 629S. [Abstract] [Full Text] [PDF]

				J. I. Aramendi and C.-A. Mestres Antithrombotic therapy after bioprosthetic aortic valve replacement Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 529 - 530. [Full Text] [PDF]

				J. Nowell and M. Jahangiri Antiplatelet therapy after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 945 - 945. [Full Text] [PDF]

				M. Brueck, W. Kramer, P. Vogt, N. Steinert, P. Roth, G. Gorlach, M. Schonburg, and M. C. Heidt Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 108 - 112. [Abstract] [Full Text] [PDF]

				F. di Marco, S. Grendene, G. Feltrin, D. Meneghetti, and G. Gerosa Antiplatelet therapy in patients receiving aortic bioprostheses: A report of clinical and instrumental safety J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1597 - 1603. [Abstract] [Full Text] [PDF]

				A. Colli, J.-P. Verhoye, A. Leguerrier, and T. Gherli Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 573 - 577. [Abstract] [Full Text] [PDF]

				J. Nowell, E. Wilton, H. Markus, and M. Jahangiri Antithrombotic therapy following bioprosthetic aortic valve replacement Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 578 - 585. [Abstract] [Full Text] [PDF]

				W.R. E. Jamieson, S. D. Moffatt-Bruce, P. Skarsgard, M. A. Hadi, J. Ye, G. J. Fradet, J. G. Abel, M. T. Janusz, A. Cheung, and E. Germann Early Antithrombotic Therapy for Aortic Valve Bioprostheses: Is There an Indication for Routine Use? Ann. Thorac. Surg., February 1, 2007; 83(2): 549 - 557. [Abstract] [Full Text] [PDF]

				M. El-Husseiny, K. Salhiyyah, S. G. Raja, and J. Dunning Should warfarin be routinely prescribed for the first three months after a bioprosthetic valve replacement? Interactive CardioVascular and Thoracic Surgery, October 1, 2006; 5(5): 616 - 623. [Abstract] [Full Text] [PDF]

				F. di Marco, M. Giordan, and G. Gerosa Early antithrombotic therapy after aortic valve replacement with tissue valves: When the practice diverges from the guidelines J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1223 - 1223. [Full Text] [PDF]

				A. Vincentelli, B. Jude, and S. Belisle Antithrombotic therapy in cardiac surgery: [Traitement antithrombotique en chirurgie cardiaque]. Can J Anesth, June 1, 2006; 53(6_suppl): S89 - S102. [Abstract] [Full Text] [PDF]

				S. H. Rahimtoola The Year in Valvular Heart Disease J. Am. Coll. Cardiol., January 17, 2006; 47(2): 427 - 439. [Full Text] [PDF]

				E. G. Butchart, C. Gohlke-Barwolf, M. J. Antunes, P. Tornos, R. De Caterina, B. Cormier, B. Prendergast, B. Iung, H. Bjornstad, C. Leport, et al. Recommendations for the management of patients after heart valve surgery Eur. Heart J., November 2, 2005; 26(22): 2463 - 2471. [Abstract] [Full Text] [PDF]

				T.M. Sundt, K.J. Zehr, J.A. Dearani, R.C. Daly, C.J. Mullany, C.G.A. McGregor, F.J. Puga, T.A. Orszulak, and H.V. Schaff Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1024 - 1031. [Abstract] [Full Text] [PDF]

				Is Aspirin Sufficient After Biologic AVR? Journal Watch Cardiology, October 22, 2004; 2004(1022): 5 - 5. [Full Text]

				D. N. Salem, P. D. Stein, A. Al-Ahmad, H. I. Bussey, D. Horstkotte, N. Miller, and S. G. Pauker Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 457S - 482S. [Abstract] [Full Text] [PDF]